Radiation Oncology Journal

  • 제23권3호
  • /
  • Pages.137-142
  • /
  • 2005
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지

원발병소 블명의 경부림프절 전이의 치료결과

Treatment Outcome of Metastatic Carcinoma of Cervical Lymph Node from an Unknown Primary

  • 김규보 (서울대학교 의과대학 방사선종양학교실) ;
  • 지의규 (서울대학교 의과대학 방사선종양학교실) ;
  • 우홍균 (서울대학교 의과대학 방사선종양학교실, 의학연구원 방사선의학연구소) ;
  • 김광현 (서울대학교 의과대학 이비인후과학교실) ;
  • 성명훈 (서울대학교 의과대학 이비인후과학교실) ;
  • 허대석 (서울대학교 의과대학 내과학교실) ;
  • 박찬일 (서울대학교 의과대학 방사선종양학교실, 의학연구원 방사선의학연구소)
  • Kim Kyubo (Departments of Radiation Oncology, Seoul National University College of Medicine) ;
  • Chie EuiKyu (Departments of Radiation Oncology, Seoul National University College of Medicine) ;
  • Wu Hong-Gyun (Departments of Radiation Oncology, Institute on Radiation Medicine, Medical Research Center, Seoul National University College of Medicine) ;
  • Kim Kwang Hyun (Departments of Otorhinolarynogology and Head & Neck Surgery Seoul National University College of Medicine) ;
  • Sung Myung-Whun (Departments of Otorhinolarynogology and Head & Neck Surgery Seoul National University College of Medicine) ;
  • Heo Dae Seog (Departments of Internal Medicine, Seoul National University College of Medicine) ;
  • Park Charn Il (Departments of Radiation Oncology, Institute on Radiation Medicine, Medical Research Center, Seoul National University College of Medicine)
  • 발행 : 2005.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 원발병소 불명의 경부림프절 전이의 치료는 각 기관들의 치료원칙에 따라 경부림프절청소술, 림프절 절제술, 방사선치료 및 항암화학치료 등 다양한 조합의 치료가 적용되고 있다. 저자들은 서울대학교병원에서 원발병소 불명의 경부림프절 전이의 치료성적을 분석하고자 하였다. 대상 및 방법: 1981년 7월부터 1999년 6월까지 서울대학교병원 방사선종양학과에서 근치적 또는 수술 후 방사선치료를 받은 39명의 환자들을 대상으로 후향적으로 분석하였다. 방사선치료가 12명에서, 선행항암화학요법 및 방사선치료가 8명에서, 수술 및 수술 후 방사선치료가 18명에서 시행되었고, 1명은 선행항암화학요법, 경부림프절청소청술 및 수술 후 방사선치료를 받았다. 성별은 남자가 31명, 여자가 8명이었고, 연령의 중앙값은 55세였다. 결과: 전체 환자의 5년 생존율은 $55\%$였다. 치료방법에 따라 분석해보았을 때, 수술+방사선치료가 방사선 치료 단독 혹은 항암화학요법+방사선치료에 비해 우월한 5년 무병생존율을 보고하였다 ($78\%\;vs.\;48\%\;vs.\;19\%$). 그 외에 원발병소 발현여부가 무병생존율에 유의한 영향을 주는 것으로 나타났다. 결론: 원발병소 불명의 경부림프절 전이의 치료에 있어서 수술적 절제술 및 방사선치료의 병용요법이 방사선치료$\pm$항암화학요법에 비해 우월한 무병생존율을 보여주었다. 항암화학요법의 효과에 대해서는 추가 연구가 요망된다.

Purpose: To analyze the outcome of radiation therapy for patients with a metastatic carcinoma of cervical lymph nodes from an unknown primary (MUO), and identify the prognostic factors for these patients. Materials and Methods: Between July 1981 and June 1999, 39 patients with MUO underwent radiation therapy with curative intent. Twelve patients were treated with radiation therapy alone (Group 1), 8 with neoadjuvant chemotherapy followed by radiation therapy (Group 2), and 19 with either an excision or neck dissection and postoperative radiation therapy (Group 3). There were 31 males and 8 females, with a median age of 55 years, ranging from 25 to 77 ears. The median duration of follow-up was 38 months, ranging from 3 to 249 months. Results: The 5-year overall survival rate was $55\%$. According to the treatment modality, the 5-year disease-free survival rates of Groups 1, 2 and 3 were 48, 19 and $75\%$, respectively (p=0.0324). In addition to the treatment modality, the appearance of the primary site was a significant prognostic factor for disease-free survival (p=0.0085). Conclusion: Surgical resection and radiation therapy achieves a superior disease-free survival compared to radiation therapy alone, either with or without chemotherapy Further investigation Is needed to evaluate the role of chemotherapy in the treatment of MUO.

키워드

참고문헌

  1. ESMO Guideline Task Force. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol 2001; 12:1057-1058 https://doi.org/10.1023/A:1017409423484
  2. Million RR, Nicholas JC, Mancuso AA. The unknown primary. In: Million RR, Cassisi NT, eds. Management of Head and Neck Cancer: a Multidisciplinary Approach, 2nd ed. Philadelphia: JB Lippincott, 1994;311-320
  3. Coster JR, Foote RL, Olsen KD, et al. Cervical nodal metastasis of squamous cell carcinoma of unknown origin: indications for withholding radiation therapy. Int J Radiat Oncol Biol Phys 1992;23:743-749 https://doi.org/10.1016/0360-3016(92)90647-Z
  4. Wang RC, Goepfert H, Barber AE, Wolf P. Unknown primary squamous cell carcinoma metastatic to the neck. Arch Otolaryngol Head Neck Surg 1990;116:1388-1393 https://doi.org/10.1001/archotol.1990.01870120034004
  5. Iganej S, Kagan R, Anderson P, et al. Metastatic squamous cell carcinoma of the neck from an unknown primary: management options and patterns of relapse. Head Neck 2002;24:236-246 https://doi.org/10.1002/hed.10017
  6. Marcial-Vega VA, Cardenes H, Perez CA, et al. Cervical metastases from unknown primaries: radiotherapeutic management and appearance of subsequent primaries. Int J Radiat Oncol Biol Phys 1990;19:919-928 https://doi.org/10.1016/0360-3016(90)90013-A
  7. Weir L, Keane T, Cummings B, et al. Radiation treatment of cervical lymph node metastases from an unknown primary: An analysis of outcome by treatment volume and other prognostic factors. Radiother Oncol 1995;35:206-211 https://doi.org/10.1016/0167-8140(95)01559-Y
  8. Maulard C, Housset M, Brunel P, et al. Postoperative radiation therapy for cervical lymph node metastases from an occult squamous cell carcinoma. Laryngoscope 1992;102:884-890 https://doi.org/10.1288/00005537-199208000-00007
  9. Davison BJ, Spiro RH, Patel S, Patel K, Shah JP. Cervical metastases of occult origin: the impact of combined modality therapy. Am J Surg 1994;168:395-399 https://doi.org/10.1016/S0002-9610(05)80083-2
  10. Colletier PJ, Garden AS, Morrison WH, Goepfert H, Geara F, Ang KK. Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: outcomes and patterns of failure. Head Neck 1998;20:674-681 https://doi.org/10.1002/(SICI)1097-0347(199812)20:8<674::AID-HED3>3.0.CO;2-H
  11. American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Handbook. 6th ed. New York: Springer- Verlag; 2002. p17-87
  12. Kaplan EL, Meier PI. A nonparametric estimation from incomplete observations. J Am Statics Assoc 1958;53:457-481 https://doi.org/10.2307/2281868
  13. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346 https://doi.org/10.1016/0360-3016(95)00060-C
  14. Mack Y, Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. Squamous cell carcinoma of the head and neck: management after excisional biopsy of a solitary metastatic neck node. Int J Radiat Oncol Biol Phys 1993;25:619-622 https://doi.org/10.1016/0360-3016(93)90007-I
  15. Reddy SP, Marks JE. Metastatic carcinoma in the cervical lymph nodes from an unknown primary site: results of bilateral neck plus mucosal irradiation vs. ipsilateral irradiation. Int J Radiat Oncol Biol Phys 1997;37:797-802 https://doi.org/10.1016/S0360-3016(97)00025-4
  16. Lefebvre JL, Coche-Dequeant B, Van JT, Buisset E, Adenis A. Cervical lymph nodes from an unknown primary tumor in 190 patients. Am J Surg 1990;160:443-446 https://doi.org/10.1016/S0002-9610(05)80562-8
  17. DeBraud F, Heilbrun LK, Ahmed K, et al. Metastatic squamous cell carcinoma of an unknown primary localized to the neck: advantages of an aggressive treatment. Cancer 1989;64:510-515 https://doi.org/10.1002/1097-0142(19890715)64:2<510::AID-CNCR2820640225>3.0.CO;2-2
  18. Park IK, Yun CM, Kim JC. Radiotherapy for metastatic neck nodes from an unknown primary site. J Korean Soc Ther Oncol 1997;15:105-111
  19. Jakobsen J, Aschenfeldt P, Johansen J, Jorgensen K. Lymph node metastases in the neck from unknown primary tumour. Acta Oncologica 1992;31:653-655 https://doi.org/10.3109/02841869209083848